PRLD — Prelude Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $196.96m
- $93.74m
- $12.14m
Annual income statement for Prelude Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 7 | 12.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 114 | 124 | 132 | 147 | 117 |
| Operating Profit | -114 | -124 | -132 | -140 | -105 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -112 | -115 | -122 | -127 | -99.5 |
| Net Income After Taxes | -112 | -115 | -122 | -127 | -99.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -112 | -115 | -122 | -127 | -99.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -112 | -115 | -122 | -127 | -99.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.43 | -2.44 | -2.02 | -1.68 | -1.29 |